GSK is a science-led global healthcare company with a mission to help people do more, feel better and live longer. We research and develop a broad range of innovative products in three primary areas – pharmaceuticals, vaccines and consumer healthcare – that aim to improve people’s health and well-being, ultimately helping them to live life to its fullest and contribute to the prosperity of their communities.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies, bringing differentiated, high-quality and needed healthcare products to as many people as possible.
The Menarini Group, with its headquarters in Florence, is present in 136 countries around the world with 17,000 employees. With a turnover of 3.6 billion Euro, Menarini today is 13th in Europe out of 5,345 companies and 35th worldwide out of 21,587 (source: IQVIA). Menarini has 6 Research & Development centres and its products are present in the most important therapeutic areas including cardiology, gastroenterology, pneumology, infectious disease, diabetology, anti-inflammatory agents and analgesics. Menarini’s products are manufactured in the Group’s 16 production sites, in Italy and abroad, where more than 583 million packs are produced and distributed over five continents each year. Through its pharmaceutical products, Menarini contributes continuously and with the highest quality standard towards the health of patients all around the world. For further information: www.menarini.com
Menarini is committed to building a strong anti-infectives portfolio; comprised of premium and specialist products. The new Infection in focus identity is a symbol of our commitment. Beyond commitment to product innovation, Menarini is committing to playing a key role in changing the anti-infectives market. In short, Menarini are putting infection in focus.
Our core product categories include diabetes, cancer, vaccines and hospital acute care. We continue to focus our research on conditions that represent some of today’s most significant health challenges – like cancer, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and Alzheimer’s disease, and we are on the front lines in the fight against emerging global pandemics, such as ebola. We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them. At MSD, we’re applying our global reach, financial strength and scientific excellence to do more of what we’re passionate about: improving health and improving lives. For more information, visit www.msd-singapore.com.
At Pfizer Singapore, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care in Singapore.